Optogenetic therapeutic strategies for diabetes mellitus
Xin Deng1,2, Dandan Peng1, Yuanfa Yao2
1Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
Abstract:
Diabetes mellitus (DM) is a common chronic disease affecting humans globally. It is characterized by abnormally elevated blood glucose levels due to the failure of insulin production or reduction of insulin sensitivity and functionality. Insulin and glucagon-like peptide (GLP)-1 replenishment or improvement of insulin resistance are the two major strategies to treat diabetes. Recently, optogenetics that uses genetically encoded light-sensitive proteins to precisely control cell functions has been regarded as a novel therapeutic strategy for diabetes. Here, we summarize the latest development of optogenetics and its integration with synthetic biology approaches to produce light-responsive cells for insulin/GLP-1 production, amelioration of insulin resistance and neuromodulation of insulin secretion. In addition, we introduce the development of cell encapsulation and delivery methods and smart bioelectronic devices for the in vivo application of optogenetics-based cell therapy in diabetes. The remaining challenges for optogenetics-based cell therapy in the clinical translational study are also discussed.
Insights
Optogenetics offers a novel approach to diabetes treatment by using light to control cells for insulin production and improved insulin sensitivity. This innovative therapy shows promise for managing diabetes through precise cellular modulation.
Area of Science:
- Biotechnology
- Cell Biology
- Endocrinology
Background:
- Diabetes mellitus (DM) is a global chronic disease characterized by high blood glucose.
- Current treatments focus on insulin/glucagon-like peptide (GLP)-1 replenishment or improving insulin resistance.
Purpose of the Study:
- To review the latest advancements in optogenetics for diabetes therapy.
- To explore the integration of optogenetics with synthetic biology for novel diabetes treatments.
Main Methods:
- Utilizing genetically encoded light-sensitive proteins to control cell functions.
- Developing light-responsive cells for therapeutic agent production (insulin/GLP-1).
- Investigating methods for cell encapsulation, delivery, and bioelectronic devices for in vivo applications.
Main Results:
- Optogenetics enables precise control over insulin/GLP-1 production and insulin resistance amelioration.
- Synthetic biology approaches enhance the development of light-responsive cells.
- Advancements in delivery systems and bioelectronic devices facilitate in vivo optogenetic therapy.
Conclusions:
- Optogenetics represents a promising novel therapeutic strategy for diabetes management.
- Further research and clinical translation are needed to address remaining challenges in optogenetic cell therapy for diabetes.
More Related Videos
10:07Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
Published on: December 26, 2017
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...